



**Lesotho**

**Country Operational Plan**

**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		1,045,000		1,045,000	0
HHS/CDC	512,500	13,683,851		14,196,351	0
PC		637,000		637,000	0
State		200,000		200,000	0
State/AF		150,000		150,000	0
USAID		16,296,649	6,400,000	22,696,649	275,000
<b>Total</b>	<b>512,500</b>	<b>32,012,500</b>	<b>6,400,000</b>	<b>38,925,000</b>	<b>275,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold	Total
	State	DOD	HHS/CDC	PC	State/AF	USAID	Amount	
CIRC		308,000	0			1,707,650	0	2,015,650
HBHC	3,131	178,000	804,587		60,000	1,228,866	0	2,274,584
HKID	2,087			203,198	30,000	2,537,314	0	2,772,599
HLAB		58,000	687,379				0	745,379
HMBL			0				0	0
HTXS		206,000	4,153,121			6,750,343	0	11,109,464
HVCT			1,219,387			20,032	0	1,239,419
HVMS	191,651	79,000	1,651,707	114,862		1,907,399	0	3,944,619
HVOP		108,000		318,940		776,038	0	1,202,978
HVSI		108,000	900,015			480,814	0	1,488,829
HVTB			1,937,683			1,758,391	0	3,696,074
MTCT			498,000			1,282,835	0	1,780,835
OHSS			133,359			830,247	0	963,606
PDCS	3,131		873,370		60,000	1,320,254	0	2,256,755
PDTX			1,337,743			2,096,466	0	3,434,209



	200,000	1,045,000	14,196,351	637,000	150,000	22,696,649	0	38,925,000
--	---------	-----------	------------	---------	---------	------------	---	------------



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,163,284	0
HKID	2,582,264	0
HVTB	3,458,593	0
PDCS	2,146,878	0
<b>Total Technical Area Planned Funding:</b>	<b>10,351,019</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	657,363	0
HVSI	786,640	0
OHSS	609,873	0
<b>Total Technical Area Planned Funding:</b>	<b>2,053,876</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	1,747,210	0
HMBL	0	0
HVCT	1,099,363	0
HVOP	797,785	0
MTCT	1,710,716	0
<b>Total Technical Area Planned Funding:</b>	<b>5,355,074</b>	<b>0</b>



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXS	10,842,586	0
PDTX	3,317,445	0
<b>Total Technical Area Planned Funding:</b>	<b>14,160,031</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	98 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,936	32,813
	Number of new ANC and L&D clients	12,164	34,643
	By: Known positives at entry	1,666	4,723
	By: Number of new positives identified	1,422	4,645
	Sum of Positives Status disaggregates	3,088	9,368
	Required only for DREAMS Countries - By Number of new positives: <15		0
	Required only for DREAMS Countries - By Number of new positives: 15-19		0
	Required only for DREAMS Countries - By Number of new positives: 20-24		0
	Required only for DREAMS Countries - By Number of new positives: 25+		0

	Required only for DREAMS Countries - By Number of known positives: <15		0
	Required only for DREAMS Countries - By Number of known positives: 15-19		0
	Required only for DREAMS Countries - By Number of known positives: 20-24		0
	Required only for DREAMS Countries - By Number of known positives: 25+		0
	Required only for DREAMS Countries - Denominator: <15		0
	Required only for DREAMS Countries - Denominator: <15-19		0
	Required only for DREAMS Countries - Denominator: 20-24		0
	Required only for DREAMS Countries - Denominator: 25+		0
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	98 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	29,998	0

	Number of new ANC and L&D clients	30,556	0
	By: Known positives at entry	3,758	0
	By: Number of new positives identified	4,030	0
	Sum of Positives Status disaggregates	7,788	0
	Required only for DREAMS countries - By known positives: <15		0
	Required only for DREAMS countries - By known positives: 15-19		0
	Required only for DREAMS countries - By known positives: 20-24		0
	Required only for DREAMS countries - By known positives: 25+		0
	Required only for DREAMS countries - By new positives: <15		0
	Required only for DREAMS countries - By new positives: 15-19		0
	Required only for DREAMS countries - By new positives: 20-24		0
	Required only for DREAMS countries - By new positives: 25+		0
	Required only for DREAMS countries - Denominator: <15		0
	Required only for DREAMS countries - Denominator:		0



	15-19		
	Required only for DREAMS countries - Denominator: 20-24		0
	Required only for DREAMS countries - Denominator: 25+		0
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,839	9,070
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,013	9,325
	Life-long ART (including Option B+)	3,839	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,697	3,707
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,142	5,363

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	3,839	0
	Sum of New and Current disaggregates	3,839	9,070
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	7,767	0
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	8,099	0

	Life-long ART (including Option B+)	7,767	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5,807	0
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,960	0
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	7,767	0
	Sum of New and Current disaggregates	7,767	0
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		15,503
	Number of HIV-exposed infants registered in the birth		15,503

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		732
	HIV-infected: Not linked to ART		0
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		9,876
	HIV-uninfected: Still breastfeeding		4,872
	HIV-uninfected: Breastfeeding status unknown		0
	Other: In care but no test done		0
	Other: Lost to follow-up		0
	Other: Died		21
	Other: Transferred out		0
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		0
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		0
	HIV-infected: Linked to ART		0

	HIV-infected: Not linked to ART		0
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		0
	HIV-uninfected: Not breastfeeding		0
	HIV-uninfected: Still breastfeeding		0
	Other: Died		0
	Other: In care but no test done		0
	Other: Lost to follow-up		0
	Other: Transferred out		0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)		525
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by		

	maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by		

	maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	61,500	23,524
	By Age: <1		0
	By Age: 1-9		0
	By Age: 10-14	11,225	610
	By Age: 15-19	22,235	7,738
	By Age: 20-24	11,370	7,356
	By Age: 25-29		7,308
	By Age: 30-49		512
	By Age: 50+	475	0
	Sum of age disaggregates	61,500	15,704
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	3,321	1,227
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	52,029	19,033
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	6,150	3,263
	By circumcision technique: Surgical VMMC	55,500	23,503
By circumcision technique:	6,000	1	

	Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	55,950	18,449
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	5,550	5,075
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,500	
	By Age: <1	1,500	
	By Age: 1-9	0	
	By Age: 10-14	0	
	By Age: 15-19	0	
	By Age: 20-24	0	
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	0	
	Sum of Age disaggregations	1,500	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	



	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	150	
	By circumcision technique: Surgical VMMC	1,500	
	By circumcision technique: Device-based VMMC	0	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,350	
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	150	0
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	55,000	72,183
	Total number of people in the target population		387,070

	Age/sex: 10-14 Male	0	0
	Age/sex: 15-19 Male	2,021	0
	Age/sex: 20-24 Male	9,604	11,325
	Age/sex: 25-49 Male	30,502	15,648
	Age/sex: 50+ Male	0	0
	Age/sex: 10-14 Female	0	9,817
	Age/sex: 15-19 Female	1,800	17,731
	Age/sex: 20-24 Female	6,168	17,662
	Age/sex: 25-49 Female	4,905	0
	Age/sex: 50+ Female	0	0
	Sum of Age/Sex disaggregates	55,000	72,183
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,000	5,459
	Total estimated number of key population in the catchment area		7,321
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group	0	2,079

	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,000	3,380
	By key population type: MSM/TG who are male sex	0	

	workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		2,671
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex		

	workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	195,365	565,888
	By Test Result: Negative	164,946	497,235
	By Test Result: Positive	30,419	68,653
	Sum of Test Result disaggregates	195,365	565,888
	Test Result by Age and Sex: Positive: <1 Male		49
	Test Result by Age and Sex: Positive: 1-4 Male		292
	Test Result by Age and Sex: Positive: 5-9 Male		299
	Test Result by Age and Sex: Positive: 10-14 Male		464
	Test Result by Age and Sex: Positive: 15-19 Male		1,401
	Test Result by Age and Sex: Positive: 20-24 Male		4,461
	Test Result by Age and Sex: Positive: 25-49 Male		16,700
	Test Result by Age and Sex: Positive: 50+ Male		2,932
	Test Result by Age and Sex: Positive: <1 Female		118
	Test Result by Age and Sex: Positive: 1-4 Female		412



	Test Result by Age and Sex: Positive: 5-9 Female		427
	Test Result by Age and Sex: Positive: 10-14 Female		1,284
	Test Result by Age and Sex: Positive: 15-19 Female		3,084
	Test Result by Age and Sex: Positive: 20-24 Female		8,871
	Test Result by Age and Sex: Positive: 25-49 Female		21,005
	Test Result by Age and Sex: Positive: 50+ Female		5,203
	Test Result by Age and Sex: Negative: <1 Male		2,115
	Test Result by Age and Sex: Negative: 1-4 Male		9,270
	Test Result by Age and Sex: Negative: 5-9 Male		8,143
	Test Result by Age and Sex: Negative: 10-14 Male		12,748
	Test Result by Age and Sex: Negative: 15-19 Male		24,711
	Test Result by Age and Sex: Negative: 20-24 Male		43,684
	Test Result by Age and Sex: Negative: 25-49 Male		72,682
	Test Result by Age and Sex: Negative: 50+ Male		23,149
	Test Result by Age and Sex: Negative: <1 Female		2,319
	Test Result by Age and Sex: Negative: 1-4 Female		10,369
	Test Result by Age and Sex: Negative: 5-9 Female		10,306

	Test Result by Age and Sex: Negative: 10-14 Female		22,797
	Test Result by Age and Sex: Negative: 15-19 Female		43,391
	Test Result by Age and Sex: Negative: 20-24 Female		63,535
	Test Result by Age and Sex: Negative: 25-49 Female		104,453
	Test Result by Age and Sex: Negative: 50+ Female		45,214
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,503	33,219
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	84,864	189,840
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,445	47,648
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	100,553	295,140
	Sum of Aggregated Age/Sex <15	9,948	80,867
	Sum of Aggregated Age/Sex 15+	185,417	484,980
	Sum of Aggregated Age/Sex disaggregates	195,365	565,847
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		4,712

	Service Delivery Point by Result: Antenatal Clinic - Negative		23,689
	Service Delivery Point by Result: Labor & delivery - All results		325
	Service Delivery Point by Result: Labor & delivery - Positive		75
	Service Delivery Point by Result: Labor & delivery - Negative		250
	Service Delivery Point by Result: Under 5 Clinic – All results		1,127
	Service Delivery Point by Result: Under 5 Clinic - Positive		70
	Service Delivery Point by Result: Under 5 Clinic - Negative		1,057
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		9
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		1
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		8
	Service Delivery Point by Result: Tuberculosis – All results		9,513
	Service Delivery Point by Result: Tuberculosis -		5,511



	Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		4,007
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		56
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		20
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		36
	Service Delivery Point by Result: Outpatient Department – All Results		337,322
	Service Delivery Point by Result: Outpatient Department - Positive		37,724
	Service Delivery Point by Result: Outpatient Department - Negative		299,593
	Service Delivery Point by Result: Inpatient – All Results		3,637
	Service Delivery Point by Result: Inpatient - Positive		278
	Service Delivery Point by Result: Inpatient - Negative		3,359
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		0
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		0

	Service Delivery Point by Result: HIV care and treatment clinic - Negative		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		20,020
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		2,001
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		18,698
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		17
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		220
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		232
	Service Delivery Point by Result: Voluntary Counseling		2,113

	& Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		65,355
	Service Delivery Point by Result: Mobile - Positive		10,090
	Service Delivery Point by Result: Mobile - Negative		55,265
	Service Delivery Point by Result: Home-based – All Results		96,861
	Service Delivery Point by Result: Home-based - Positive		8,110
	Service Delivery Point by Result: Home-based - Negative		88,751
	Service Delivery Point by Result: Other – All Results		0
	Service Delivery Point by Result: Other - Positive		0
	Service Delivery Point by Result: Other - Negative		0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	222,607	0
	By Test Result: Negative	181,219	0
	By Test Result: Positive	41,388	0
	Sum of Test Result disaggregates	222,607	0
	Test Result by Age and Sex: Positive: <1 Male		0



	Test Result by Age and Sex: Positive: 1-4 Male		0
	Test Result by Age and Sex: Positive: 5-9 Male		0
	Test Result by Age and Sex: Positive: 10-14 Male		0
	Test Result by Age and Sex: Positive: 15-19 Male		0
	Test Result by Age and Sex: Positive: 20-24 Male		0
	Test Result by Age and Sex: Positive: 25-49 Male		0
	Test Result by Age and Sex: Positive: 50+ Male		0
	Test Result by Age and Sex: Positive: <1 Female		0
	Test Result by Age and Sex: Positive: 1-4 Female		0
	Test Result by Age and Sex: Positive: 5-9 Female		0
	Test Result by Age and Sex: Positive: 10-14 Female		0
	Test Result by Age and Sex: Positive: 15-19 Female		0
	Test Result by Age and Sex: Positive: 20-24 Female		0
	Test Result by Age and Sex: Positive: 25-49 Female		0
	Test Result by Age and Sex: Positive: 50+ Female		0
	Test Result by Age and Sex: Negative: <1 Male		0
	Test Result by Age and Sex: Negative: 1-4 Male		0

	Test Result by Age and Sex: Negative: 5-9 Male		0
	Test Result by Age and Sex: Negative: 10-14 Male		0
	Test Result by Age and Sex: Negative: 15-19 Male		0
	Test Result by Age and Sex: Negative: 20-24 Male		0
	Test Result by Age and Sex: Negative: 25-49 Male		0
	Test Result by Age and Sex: Negative: 50+ Male		0
	Test Result by Age and Sex: Negative: <1 Female		0
	Test Result by Age and Sex: Negative: 1-4 Female		0
	Test Result by Age and Sex: Negative: 5-9 Female		0
	Test Result by Age and Sex: Negative: 10-14 Female		0
	Test Result by Age and Sex: Negative: 15-19 Female		0
	Test Result by Age and Sex: Negative: 20-24 Female		0
	Test Result by Age and Sex: Negative: 25-49 Female		0
	Test Result by Age and Sex: Negative: 50+ Female		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,689	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	96,697	0

	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,646	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	114,575	0
	Sum of Aggregated Age/Sex <15	11,335	0
	Sum of Aggregated Age/Sex 15+	211,272	0
	Sum of Aggregated Age/Sex disaggregates	222,607	0
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		0
	Service Delivery Point by Result: Antenatal Clinic - Negative		0
	Service Delivery Point by Result: Labor & delivery - All results		0
	Service Delivery Point by Result: Labor & delivery - Positive		0
	Service Delivery Point by Result: Labor & delivery - Negative		0
	Service Delivery Point by Result: Under 5 Clinic – All results		0
	Service Delivery Point by Result: Under 5 Clinic -		0

	Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		0
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		0
	Service Delivery Point by Result: Tuberculosis – All results		0
	Service Delivery Point by Result: Tuberculosis - Positive		0
	Service Delivery Point by Result: Tuberculosis - Negative		0
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		0
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		0
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		0
	Service Delivery Point by Result: Outpatient Department – All Results		0
	Service Delivery Point by		0

	Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		0
	Service Delivery Point by Result: Inpatient – All Results		0
	Service Delivery Point by Result: Inpatient - Positive		0
	Service Delivery Point by Result: Inpatient - Negative		0
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		0
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		0
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		



	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		0
	Service Delivery Point by Result: Mobile – All Results		0
	Service Delivery Point by Result: Mobile - Positive		0
	Service Delivery Point by Result: Mobile - Negative		0
	Service Delivery Point by Result: Home-based – All Results		0
	Service Delivery Point by Result: Home-based - Positive		0
	Service Delivery Point by Result: Home-based - Negative		0
	Service Delivery Point by		0

	Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		0
	Service Delivery Point by Result: Other - Negative		0
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		0
	Test Result by Aggregated Age and Sex: Negative <15 Female		0
	Test Result by Aggregated Age and Sex: Negative 15+ Female		0
	Test Result by Aggregated Age and Sex: Positive <15 Male		0
	Test Result by Aggregated Age and Sex: Positive 15+ Male		0
	Test Result by Aggregated Age and Sex: Positive <15 Female		0
	Test Result by Aggregated Age and Sex: Positive 15+ Female		0
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new		8,467

	and relapsed TB cases with documented HIV status, during the reporting period.		
	Total number of registered new and relapsed TB cases, during the reporting period.		8,467
	Sex: Male		4,823
	Sex: Female		3,642
	Age: <1		12
	Age: 1-4		36
	Age: 5-9		44
	Age: 10-14		128
	Age 15-19		
	Age: 20+		7,901
	Status: Positive		5,433
	Status: Negative		3,033
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		0
	Total number of registered new and relapsed TB cases, during the reporting period.		0
	Age 15-19		
	Age: <1		0
	Age: 1-4		0
	Age: 10-14		0
	Age: 20+		0
	Age: 5-9		0

	Sex: Female		0
	Sex: Male		0
	Status: Negative		0
	Status: Positive		0
GEND_GBVDSD	Number of people receiving post-GBV care		676
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-17 Male		0
	Age/Sex: 18-24 Male		0
	Age/Sex: 25+ Male		0
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		65
	Age/Sex: 15-17 Female		172
	Age/Sex: 18-24 Female		439
	Age/Sex: 25+ Female		0
	Sum of Age/Sex Disaggregates		676
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)		70
	By type of service: Sexual Violence (Post-Rape Care)		606
	By PEP service provision (related to sexual violence services provided)		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		21,308
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-19 Male		0

	Age/Sex: 20-24 Male		8,524
	Age/Sex: 25+ Male		12,784
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-19 Female		0
	Age/Sex: 20-24 Female		0
	Age/Sex: 25+ Female		0
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	15,773	23,550
	Age/Sex: <1 Male		155
	Age/Sex: 1-4 Male		1,813
	Age/Sex: 5-9 Male		2,048
	Age/Sex: 10-14 Male		1,888
	Age/Sex: 15-17 Male		2,114
	Age/Sex: 18-24 Male		2,132
	Age/Sex: 25+ Male		2,139
	Age/Sex: <1 Female		149
	Age/Sex: 1-4 Female		1,838
	Age/Sex: 5-9 Female		1,758
	Age/Sex: 10-14 Female		1,652
	Age/Sex: 15-17 Female		1,644
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		1,637

	Age/Sex: 25+ Female		2,596
	Sum of Age/Sex disaggregates		23,563
OVC_ACC_TA	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		2,207
	Age/Sex: <1 Male		14
	Age/Sex: 1-4 Male		133
	Age/Sex: 5-9 Male		111
	Age/Sex: 10-14 Male		112
	Age/Sex: 15-17 Male		186
	Age/Sex: 18-24 Male		192
	Age/Sex: 25+ Male		192
	Age/Sex: <1 Female		20
	Age/Sex: 1-4 Female		101
	Age/Sex: 5-9 Female		150
	Age/Sex: 10-14 Female		149
	Age/Sex: 15-17 Female		148
	Age/Sex: 18-24 Female		148
	Age/Sex: 25+ Female		217
	Sum of Age/Sex disaggregates		1,873
	OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	24,100
Age/Sex: <1 Male			441
Age/Sex: 1-4 Male			3,860
Age/Sex: 5-9 Male			3,685
Age/Sex: 10-14 Male			8,486

	Age/Sex: 15-17 Male		9,094
	By: Age/sex: Male 18-24		6,130
	By: Age/sex: Male 25+		4,164
	Age/Sex: <1 Female		483
	Age/Sex: 1-4 Female		3,882
	Age/Sex: 5-9 Female		3,179
	Age/Sex: 10-14 Female		11,891
	Age/Sex: 15-17 Female		8,189
	By: Age/sex: 18-24 Female		7,893
	By: Age/sex: 25+ Female		5,045
	Sum of Age/Sex disaggregates		53,190
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age		



	and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS		



	countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection		

	Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age		

	and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		4,864
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		2,810
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		6,111
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		2,114
	Required only for DREAMS		

	countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		1,159
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		2,857
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		4,103
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		1,713
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	956	4,232
	Age/Sex: <1 Male		53
	Age/Sex: 1-4 Male		341
	Age/Sex: 5-9 Male		342



	Age/Sex: 10-14 Male		342
	Age/Sex: 15-17 Male		369
	By age/sex: 18-24 Male		381
	By age/sex: 25+ Male		400
	Age/Sex: <1 Female		46
	Age/Sex: 1-4 Female		332
	Age/Sex: 5-9 Female		293
	Age/Sex: 10-14 Female		293
	Age/Sex: 15-17 Female		291
	By age/sex: 18-24 Female		291
	By age/sex: 25+ Female		438
	Sum of Age/Sex disaggregates		2,360
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		0
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		0
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS		0



	countries: By Service Area, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		0
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		0
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		25
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS		0





	countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		25
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		25
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		271
	Required only for DREAMS countries: By Service Area,		

	age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		0
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		5
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		5
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		0
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		0
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		

	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		25
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		0
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		0
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		0
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		25
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		25
	Required only for DREAMS countries: By Service Area, age and sex: Economic		40

	Strengthening Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		271
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		20
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		15
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		15
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who	79,007	165,216

	received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male		467
	Age/sex: 1-4 Male		1,220
	Age/sex: 5-9 Male		1,563
	Age/sex: 10-14 Male		1,675
	Age/sex: 15-19 Male		1,389
	Age/sex: 20-24 Male		2,969
	Age/sex: 25-49 Male		36,473
	Age/sex: 50+ Male		10,154
	Age/sex: <1 Female		467
	Age/sex: 1-4 Female		1,220
	Age/sex: 5-9 Female		1,563
	Age/sex: 10-14 Female		1,665
	Age/sex: 15-19 Female		4,202
	Age/sex: 20-24 Female		20,194
	Age/sex: 25-49 Female		67,230
	Age/sex: 50+ Female		12,801
	Sun of Age/Sex disaggregates		165,252
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,336	20
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,492	1,562
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,597	10
	Aggregated Age/sex - USE	48,582	726

	WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates	79,007	2,318
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	215,277	
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,737	
	Aggregated Age/sex - USE	59,111	

	WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,339	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	127,090	
	Sum of Aggregated Age/Sex disaggregates	215,277	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	52,253	64,589
	Age/sex: <1 Male		296
	Age/sex: 1-4 Male		798
	Age/sex: 5-9 Male		1,020
	Age/sex: 10-14 Male		1,102
	Age/sex: 15-19 Male		448
	Age/sex: 20-24 Male		976
	Age/sex: 25-49 Male		13,729
	Age/sex: 50+ Male		3,821
	Age/sex: <1 Female		297
	Age/sex: 1-4 Female		795
	Age/sex: 5-9 Female		1,020
	Age/sex: 10-14 Female		1,091
	Age/sex: 15-19 Female		1,514
	Age/sex: 20-24 Female		7,578
Age/sex: 25-49 Female		25,297	



	Age/sex: 50+ Female		4,806
	Sum of Age/sex disaggregates		64,588
	Aggregated Age/sex: <15 Male	2,631	20
	Aggregated Age/sex: 15+ Male	21,007	366
	Aggregated Age/sex: <15 Female	2,945	5
	Aggregated Age/sex: 15+ Female	25,670	209
	Sum of Aggregated Age/sex disaggregates	52,253	600
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	80 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,839	691
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,286	691
	Age: <1	0	106
	Age: 1-4	0	173
	Age: 5-14	0	394
	Age: 15-17	368	18
	Age: 18+	1,471	0
	Sum of Age disaggregates	1,839	691
	Aggregated Age: <18	368	0

	Aggregated Age: 18+	1,471	0
	Sum of Aggregated Age disaggregates	1,839	0
	By Pregnancy/Postpartum Status: Pregnant		0
	By Pregnancy/Postpartum Status: Postpartum		0
FN_THER_TA	FN_THER_TA Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	n/a	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.		0
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.		
	Age: <1		
	Age: 1-4		
	Age: 5-14		
	Age: 15-17		
	Age: 18+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <18		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 18+		
	By Pregnancy/Postpartum		

	Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
	Sum of Aggregated Age disaggregates		
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		51,458
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		489
	Age: 1-4		1,283
	Age: 5-9		1,647
	Age: 10-14		1,737
	Age: 15-19		1,459
	Age: 20+		44,843
	Sum of Age disaggregates		51,458
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		0
	Age (Aggregated)- USE WITH HQ PERMISSION		0

	ONLY: 15+		
	Sex: Male		17,526
	Sex: Female		33,932
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		0
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		0
	Age: 20+		0
	Sum of Age disaggregates		0
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		0
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		0

	Sex: Male		0
	Sex: Female		0
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		6,244
	Number of HIV positive adults and children who received care and treatment services		6,808
	Age: <1		729
	Age: 1-4		1,740
	Age: 5-14		3,775
	Age: 15-17		0
	Age: 18+ years		0
	Sum of Age disaggregates		6,244
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		0
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		0
	By Pregnancy/Postpartum Status: Pregnant		0
	By Pregnancy/Postpartum Status: Postpartum		0
	TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases	87 %

	on ART during TB treatment		
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,546	3,569
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	12,133	5,377
	Age: <1		0
	Age: 1-4		11
	Age: 5-9		18
	Age: 10-14		47
	Age: 15-19		137
	Age: 20+		3,356
	Sum of Age disaggregates		3,569
	Male	4,218	2,030
	Female	6,328	1,539
	Sum of Sex disaggregates	10,546	3,569
	Newly tested	5,273	
	Known HIV-positive	5,273	1,800
	Sum of Test Status disaggregates	10,546	1,800
	Aggregated Age: <15	0	0
	Aggregated Age: 15+	10,546	0
	Sum of Aggregated Age disaggregates	10,546	0
	Timeliness: Art initiation <8 weeks of start of TB treatment		2,864

	Timeliness: Art initiation >8 weeks of start of TB treatment		705
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		0
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		0
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		0
	Age: 20+		0
	Sum of Age disaggregates		0
	Aggregated Age: <15		0
	Aggregated Age: 15+		0
	Sum of Aggregated Age disaggregates		0
	Male		0
	Female		0
	Sum of Sex disaggregates		0
	Known HIV-positive		0

	Newly tested		
	Sum of Test Status disaggregates		0
	Timeliness: Art initiation <8 weeks of start of TB treatment		0
	Timeliness: Art initiation >8 weeks of start of TB treatment		0
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		8,469
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		8,480
	Outcome by Age: Cured <1		5
	Outcome by Age: Cured 1-4		33
	Outcome by Age: Cured 5-9		37
	Outcome by Age: Cured 10-14		113
	Outcome by Age: Cured: 15-19		303
	Outcome by Age: Cured 20+		6,738
	Outcome by Age: Treatment Complete <1		0





	Outcome by Age: Treatment Complete 1-4		0
	Outcome by Age: Treatment Complete 5-9		0
	Outcome by Age: Treatment Complete 10-14		0
	Outcome by Age: Treatment Complete 15-19		0
	Outcome by Age: Treatment Complete 20+		0
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		17
	Outcome by Age: Treatment Failed 20+		399
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		15
	Outcome by Age: Died 20+		406
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		0



	Outcome by Age: Lost to Follow-up 10-14		0
	Outcome by Age: Lost to Follow-up 15-19		14
	Outcome by Age: Lost to Follow-up 20+		391
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not Evaluated 20+		4
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		0
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to		

	Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_OUTCOME_TA	TB_OUTCOME_TA TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		0
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		0
	Outcome by Age: Cured <1		0
	Outcome by Age: Cured 1-4		0
	Outcome by Age: Cured 5-9		0
	Outcome by Age: Cured 10-14		0
	Outcome by Age: Cured 15-19		0
	Outcome by Age: Cured 20+		0
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		



	Outcome by Age: Treatment Complete <1		0
	Outcome by Age: Treatment Complete 1-4		0
	Outcome by Age: Treatment Complete 5-9		0
	Outcome by Age: Treatment Complete 10-14		0
	Outcome by Age: Treatment Complete 15-19		0
	Outcome by Age: Treatment Complete 20+		0
	Outcome by Sex: Treatment Complete Female		0
	Outcome by Sex: Treatment Complete Male		0
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		0
	Outcome by Age: Treatment Failed 20+		0
	Outcome by Sex: Treatment Failed Female		
	Outcome by Sex: Treatment Failed Male		
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0



	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		0
	Outcome by Age: Died 20+		0
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		0
	Outcome by Age: Lost to Follow-up 10-14		0
	Outcome by Age: Lost to Follow-up 15-19		0
	Outcome by Age: Lost to Follow-up 20+		0
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not		0

	Evaluated 20+		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	95 %	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	75,057	153,482
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	79,007	165,216
	Age: <1	0	869
	Age: 1-4	0	2,289
	Age: 5-9	0	2,946
	Age: 10-14	0	3,110
	Age: 15-19	11,450	4,535
	Age: 20+		139,733
	Sum of Age disaggregates	11,450	153,482
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	0
	Aggregated Age - USE WITH HQ PERMISSION ONLY:	75,057	0

	15+		
	Sum of Aggregated Age disaggregates	75,057	0
	Sex: Male	28,427	51,140
	Sex: Female	46,630	102,342
	Sum of Sex disaggregates	75,057	153,482
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		0
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	215,277	
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		0
	Age: 20+		0
	Sum of Age disaggregates		0
Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		0	

	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		0
	Sum of Aggregated Age disaggregates		0
	Sex: Female		0
	Sex: Male		0
	Sum of Sex disaggregates		0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	80 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,216	9,566
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,250	
	By infants who received a virologic test within 2 months of birth	2,690	7,365
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,526	2,200
	Sum of Infant Age disaggregates	4,216	9,565
	By infants with a positive virologic test result within 12 months of birth		



	Number of infants with a positive virological test result within 2 months of birth		611
	Number of infants with a positive virological test result within 12 months of birth		147
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		0
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		0
	By infants who received their first virologic HIV test between 2 and 12 months of age		0
	Sum of Infant Age disaggregates		0
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		0

	Number of infants with a positive virological test result within 12 months of birth		0
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		8,719
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		0
	Number of HIV-positive pregnant women identified in the reporting period (include		

	known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		55,433
	Age/Sex: <1 Male		1,401
	Age/Sex: 1-4 Male		720
	Age/Sex: 5-9 Male		3,868
	Age/Sex: 10-14 Male		2,675
	Age/Sex: 15-19 Male		336
	Age/Sex: 20-24 Male		881
	Age/Sex: 25-49 Male		5,563
	Age/Sex: 50+ Male		1,407
	Age/Sex: <1 Female		1,531
	Age/Sex: 1-4 Female		788
	Age/Sex: 5-9 Female		4,397
	Age/Sex: 10-14 Female		3,283
	Age/Sex: 15-19 Female		2,214
	Age/Sex: 20-24 Female		9,740
	Age/Sex: 25-49 Female		14,674
	Age/Sex: 50+ Female		1,954
CARE_COMM_TA	Number of HIV-infected adults and children receiving care and support services outside of the health facility		
	Age/Sex: <1 Female		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-19 Female		0
Age/Sex: 15-19 Male		0	

	Age/Sex: 20-24 Female		0
	Age/Sex: 20-24 Male		0
	Age/Sex: 25-49 Female		0
	Age/Sex: 25-49 Male		0
	Age/Sex: 5-9 Female		0
	Age/Sex: 5-9 Male		0
	Age/Sex: 50+ Female		0
	Age/Sex: 50+ Male		0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	33,724	128,504
	Age/Sex: <1 Male		366
	Age/Sex: 1-4 Male		937
	Age/Sex: 5-14 Male		2,457
	Age/Sex: 15-19 Male		1,205
	Age/Sex: 20+ Male		38,399
	Age/Sex: <1 Female		367
	Age/Sex: 1-4 Female		932
	Age/Sex: 5-14 Female		2,453
	Age/Sex: 15-19 Female		3,297
	Age/Sex: 20+ Female		78,123
	Aggregated Age/Sex: <1 Male		0
	Aggregated Age/Sex: <1 Female		0
	Aggregated Age/Sex: 15+ Male	9,455	0
	Aggregated Age/Sex: 1-14 Female		5
	Aggregated Age/Sex: 15+ Female	20,548	629
	Sum of Aggregated Age/Sex <15	3,721	

	Sum of Aggregated Age/Sex 15+	30,003	629
	Sum of Aggregated Age/Sex disaggregates	33,724	629
	Aggregated Age/Sex: 1-14 Male		10
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		15
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	128,786	
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations		
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	36,053	
Aggregated Age/Sex: 1-14 Female			

	Aggregated Age/Sex: 15+ Female	78,734		
	Sum of Aggregated Age/Sex <15	13,999		
	Sum of Aggregated Age/Sex 15+	114,787		
	Sum of Aggregated Age/Sex disaggregates	128,786		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15			
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	17,016	44,825	
	By Age/Sex: <1 Male		268	
	By Age/Sex: 1-4 Male		672	
	By Age/Sex: 5-9 Male		873	
	By Age/Sex: 10-14 Male		929	
	By Age/Sex: 15-19 Male		314	
	By Age/Sex: 20-24 Male		686	
	By Age/Sex: 25-49 Male		9,226	
	By Age/Sex: 50+ Male		2,663	
	By Age/Sex: <1 Female		241	
	By Age/Sex: 1-4 Female		678	
	By Age/Sex: 5-9 Female		874	
	By Age/Sex: 10-14 Female		924	
	By Age/Sex: 15-19 Female		1,039	
	By Age/Sex: 20-24 Female		5,116	
	By Age/Sex: 25-49 Female		17,086	
	By Age/Sex: 50+ Female		3,234	
	Sum of Age/Sex disaggregates		44,823	
	Aggregated Grouping by Age: <1 Male			0

	Aggregated Grouping by Age/Sex: 1-14 Male		10
	Aggregated Grouping by Age/Sex: 15+ Male	4,697	365
	Aggregated Grouping by Age/Sex: <1 Female		0
	Aggregated Grouping by Age/Sex: 15+ Female	10,274	209
	Sum of Aggregated Age/Sex disaggregates	17,016	574
	Pregnancy status		2,797
	Breastfeeding status		20
	Aggregated Grouping by Age/Sex: 1-14 Female		5
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		
	By Age/Sex: 20-24 Male		
	By Age/Sex: 25-49 Male		
	By Age/Sex: 50+ Male		
	By Age/Sex: <1 Female		0
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		
	By Age/Sex: 25-49 Female		
By Age/Sex: 50+ Female			

	Sum of Age/Sex disaggregates		0
	Aggregated Grouping by Age: <1 Male		0
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		0
	Breastfeeding status		0
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	88 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,040	28,720
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,977	31,968



	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		277
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		544
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		580
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		8,653
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		272
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		540

	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		934
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		16,920
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		308
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		604
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12		584

	months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		9,462
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		309
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		599

	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,098
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		19,002
	Numerator by Status: Pregnant		7,695
	Numerator by Status: Breastfeeding		423
	Denominator by Status: Pregnant		9,014
	Denominator by Status: Breastfeeding		739
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12		

	months after initiating ART		
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are		0

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female		

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status:		



	Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		62,960
	Number of adults and children on ART at least 6 months whose medical records were reviewed		179,755
	Age/Sex: <1 Male		167
	Age/Sex: 1-4 Male		477
	Age/Sex: 5-14 Male		1,241
	Age/Sex: 15-19 Male		360
	Age/Sex: 20+ Male		18,755
	Age/Sex: <1 Female		167
	Age/Sex: 1-4 Female		475
	Age/Sex: 5-14 Female		1,240
	Age/Sex: 15-19 Female		1,505
	Age/Sex: 20+ Female		38,573
	Results Category: Undetectable		56,676
	Results Category: Detectable		6,285
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal	3	5

	acceptable level towards attainment of such accreditation		
LAB_ACC_TA	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		5
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	236	13
	By clinical laboratories	20	13
	By Point-of-care testing sites	216	0
LAB_CAP_TA	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		169
	By clinical laboratories		0
	By Point-of-care testing sites		0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	HIV serologic/diagnostic		13

	testing: Number of laboratories that perform this testing		
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		11
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		13
	CD4: Number of laboratories that perform this testing		1
	CD4: Number of laboratories that participate in this PT program		1
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	Early infant diagnostics: Number of laboratories that perform this testing		1
	Early infant diagnostics: Number of laboratories that participate in this PT program		1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	HIV viral load: Number of		1

	laboratories that perform this testing		
	HIV viral load: Number of laboratories that participate in this PT program		1
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		1
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve		1

	acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	CD4: Number of laboratories that participate in this PT program		
	CD4: Number of laboratories that perform this testing		
	Early infant diagnostics: Number of laboratories that		

	achieve acceptable successful passing criteria in this PT program		
	Early infant diagnostics: Number of laboratories that participate in this PT program		
	Early infant diagnostics: Number of laboratories that perform this testing		
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		169
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		169
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	HIV viral load: Number of laboratories that participate in this PT program		
	HIV viral load: Number of laboratories that perform this testing		

	<p>TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program</p>		
	<p>TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program</p>		
	<p>TB diagnostics (AFB microscopy): Number of laboratories that perform this testing</p>		
	<p>TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program</p>		
	<p>TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program</p>		
	<p>TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing</p>		
	<p>TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program</p>		
	<p>TB diagnostics (Culture/DST): Number of</p>		

	laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		56,620
	Number of viral load tests performed from adults and children on ART within the current reporting period		62,913
	Age/Sex: <1 Male		153
	Age/Sex: 1-4 Male		424
	Age/Sex: 5-14 Male		1,117
	Age/Sex: 15-19 Male		326
	Age/Sex: 20+ Male		16,877
	Age/Sex: <1 Female		153
	Age/Sex: 1-4 Female		424
	Age/Sex: 5-14 Female		1,119
	Age/Sex: 15-19 Female		1,352
	Age/Sex: 20+ Female		34,675
	Pregnant		490
	Breastfeeding		27
Test indication: Routine monitoring		53,790	



	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		
	Number of viral load tests performed from adults and children on ART within the current reporting period		
	Age/Sex: <1 Female		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Female		
	Age/Sex: 1-4 Male		
	Age/Sex: 15-19 Female		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Female		
	Age/Sex: 20+ Male		
	Age/Sex: 5-14 Female		
	Age/Sex: 5-14 Male		
	Breastfeeding		0
	Pregnant		
	Test indication: Routine monitoring		
	Test indication: Targeted monitoring		
HRH_PRE	Number of new HCW who graduated from a pre-service	369	468

	training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		
	By Graduates: Doctors	1	0
	By Graduates: Nurses	180	258
	By Graduates: Midwives	188	210
	By Graduates: Social service workers	0	0
	By Graduates: Laboratory professionals	0	0
	By Graduates: Other	0	0
	Sum of Graduates disaggreagtes	369	468
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	100 %	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	172	249
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	172	249
	Service delivery type: Care		84

	and Support		
	Service delivery type: Treatment		84
	Service delivery type: PMTCT		81
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7455	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	360,000
8772	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10456	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
10457	National Institute for Communicable Diseases	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10458	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
10459	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	0
10739	Ministry of Health and Social	Host Country Government	U.S. Department of Health and	GHP-State	0

	Welfare – Lesotho	Agency	Human Services/Centers for Disease Control and Prevention		
11018	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	117,000
11030	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
12098	Ministry of Health and Social Welfare – Lesotho	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13484	Population Services International	NGO	U.S. Department of Defense	GHP-State	0
13981	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,099,363
13983	Eastern, Central and Southern African Health Community Secretariat	NGO	U.S. Agency for International Development	GHP-State	0
13987	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
14072	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
14301	Population Services International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	625,785
16766	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	4,007,264
16768	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-USAID	800,000
17123	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	686,640
17401	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,235,584
17427	VISTA PARTNERS	Implementing Agency	U.S. Department of Defense	GHP-State	0
17429	Population Services International	NGO	U.S. Department of Defense	GHP-State	550,000
17430	Foundation for	NGO	U.S. Department	GHP-State	0

	Innovative New Diagnostics		of Health and Human Services/Centers for Disease Control and Prevention		
17431	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,067,400
17432	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	407,364
17467	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
17468	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	2,700,000
17547	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
17549	JHPIEGO	University	U.S. Agency for International Development	GHP-State	1,557,083
17554	TBD	TBD	Redacted	Redacted	Redacted
17557	FHI 360	NGO	U.S. Agency for International	GHP-State	0



			Development		
17622	TBD	TBD	Redacted	Redacted	Redacted
18020	TBD	TBD	Redacted	Redacted	Redacted
18048	Chemonics. Inc	Private Contractor	U.S. Agency for International Development	GHP-USAID	2,000,000
18143	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	0





## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7455</b>	<b>Mechanism Name: DOD PEPFAR Support to LDF</b>
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 360,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	360,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	100,000
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information



Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	25,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	7455		
<b>Mechanism Name:</b>	DOD PEPFAR Support to LDF		
<b>Prime Partner Name:</b>	U.S. Department of Defense (Defense)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	20,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	190,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	210	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	210	
PMTCT_ARV_TA	Life-long ART (including Option B+)	210	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	120	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	90	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	210	
PMTCT_ARV_TA	Sum of New and Current disaggregates	210	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	350	
PMTCT_STAT_TA	Number of new ANC and L&D clients	350	
PMTCT_STAT_TA	By: Known positives at entry	90	
PMTCT_STAT_TA	By: Number of new positives identified	120	
PMTCT_STAT_TA	Sum of Positives Status disaggregates	210	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	8,000	

VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	50	
VMMC_CIRC_DSD	By Age: 15-19	250	
VMMC_CIRC_DSD	By Age: 20-24	1,500	
VMMC_CIRC_DSD	By Age: 25-49	6,000	
VMMC_CIRC_DSD	By Age: 50+	200	
VMMC_CIRC_DSD	Sum of age disaggregates	8,000	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	100	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	7,800	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	100	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	3,000	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	5,000	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	7,950	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	50	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,000	
HTC_TST_DSD	By Test Result: Negative	3,000	
HTC_TST_DSD	By Test Result: Positive	1,000	
HTC_TST_DSD	Sum of Test Result disaggregates	4,000	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	

HTC_TST_DSD	Age/sex: 5-9 Male	0	
HTC_TST_DSD	Age/sex: 10-14 Male	50	
HTC_TST_DSD	Age/sex: 15-19 Male	50	
HTC_TST_DSD	Age/sex: 20-24 Male	750	
HTC_TST_DSD	Age/sex: 25-49 Male	2,500	
HTC_TST_DSD	Age/sex: 50+ Male	650	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	0	
HTC_TST_DSD	Age/sex: 10-14 Female	0	
HTC_TST_DSD	Age/sex: 15-19 Female	0	
HTC_TST_DSD	Age/sex: 20-24 Female	0	
HTC_TST_DSD	Age/sex: 25-49 Female	0	
HTC_TST_DSD	Age/sex: 50+ Female	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,000	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	500	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,500	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	500	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,500	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,000	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,000	
HTC_TST_TA	By Test Result: Negative	4,000	
HTC_TST_TA	By Test Result: Positive	2,000	
HTC_TST_TA	Sum of Test Result disaggregates	6,000	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	1,000	

	PERMISSION ONLY: <15 Male		
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,000	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,000	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,000	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	5,000	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	6,000	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,000	
CARE_CURR_TA	Age/sex: <1 Male	0	
CARE_CURR_TA	Age/sex: 1-4 Male	0	
CARE_CURR_TA	Age/sex: 5-9 Male	0	
CARE_CURR_TA	Age/sex: 10-14 Male	0	
CARE_CURR_TA	Age/sex: 15-19 Male	500	
CARE_CURR_TA	Age/sex: 20-24 Male	500	
CARE_CURR_TA	Age/sex: 25-49 Male	3,000	
CARE_CURR_TA	Age/sex: 50+ Male	2,000	
CARE_CURR_TA	Sum of Age/Sex disaggregates	6,000	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	600	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,000	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	400	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,000	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,000	

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,000	600
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	20
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,700	366
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	5
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,300	209
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,000	600
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	3,000	600
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	40	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	50	
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	0	
FN_THER_DSD	Age: 5-14	0	
FN_THER_DSD	Age: 15-17	10	
FN_THER_DSD	Age: 18+	30	
FN_THER_DSD	Sum of Age disaggregates	40	
FN_THER_DSD	Aggregated Age: <18	10	
FN_THER_DSD	Aggregated Age: 18+	30	
FN_THER_DSD	Sum of Aggregated Age disaggregates	40	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,000	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	1,000	

	period		
TB_ART_DSD	Age: 0-4	0	
TB_ART_DSD	Age: 5-14	0	
TB_ART_DSD	Age: 15+	1,000	
TB_ART_DSD	Male	700	
TB_ART_DSD	Female	300	
TB_ART_DSD	Sum of Sex disaggregates	1,000	
TB_ART_DSD	Newly tested	600	
TB_ART_DSD	Known HIV-positive	400	
TB_ART_DSD	Sum of Test Status disaggregates	1,000	
TB_ART_DSD	Aggregated Age: <15	0	
TB_ART_DSD	Aggregated Age: 15+	1,000	
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,000	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	185	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	210	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	90	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	95	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	185	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,500	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,500	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,000	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,500	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,500	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	350	589



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	40	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	165	365
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	40	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	105	209
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	350	574
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,350	1,556
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,500	1,800
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,300	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	0	

	lost to follow-up)		
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,300	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,300	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500	
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical	6,000	



	assessment (WHO staging) OR CD4 count OR viral load		
--	--------------------------------------------------------	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 8772</b>	<b>Mechanism Name: PEPFAR Laboratory Training Project</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	<b>8772</b>
----------------------	-------------



<b>Mechanism Name:</b>	<b>PEPFAR Laboratory Training Project</b>		
<b>Prime Partner Name:</b>	<b>American Society of Clinical Pathology</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	0		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10456</b>	<b>Mechanism Name: Southern Africa Building Local Capacity Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 10456			
<b>Mechanism Name:</b> Southern Africa Building Local Capacity Project			
<b>Prime Partner Name:</b> Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	15,773	
OVC_ACC_DSD	Sex: Male	6,935	
OVC_ACC_DSD	Sex: Female	8,838	
OVC_ACC_DSD	Sum of Sex disaggregates	15,773	
OVC_ACC_DSD	Age: <1	108	
OVC_ACC_DSD	Age: 1-4	1,660	
OVC_ACC_DSD	Age: 5-9	1,512	
OVC_ACC_DSD	Age: 10-14	1,188	
OVC_ACC_DSD	Age: 15-17	7,380	
OVC_ACC_DSD	Age: 18+	3,925	
OVC_ACC_DSD	Sum of Age disaggregates	15,773	
OVC_ACC_TA	Sum of Sex disaggregates	15,773	
OVC_ACC_TA	Sum of Age disaggregates	15,773	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	21,600	
OVC_SERV_DSD	Sex: Male	9,720	
OVC_SERV_DSD	Sex: Female	11,880	
OVC_SERV_DSD	Sum of Sex disaggregates	21,600	
OVC_SERV_DSD	Age: <1	76	
OVC_SERV_DSD	Age: 1-4	2,266	
OVC_SERV_DSD	Age: 5-9	3,034	
OVC_SERV_DSD	Age: 10-14	2,304	



OVC_SERV_DSD	Age: 15-17	6,720	
OVC_SERV_DSD	Age: 18+	7,200	
OVC_SERV_DSD	Sum of Age disaggregates	21,600	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	357	
OVC_SERV_TA	Sex: Male	197	
OVC_SERV_TA	Sex: Female	160	
OVC_SERV_TA	Sum of Sex disaggregates	357	
OVC_SERV_TA	Age: 18+	357	
OVC_SERV_TA	Sum of Age disaggregates	357	

### Implementing Mechanism Details

<b>Mechanism ID: 10457</b>	<b>Mechanism Name: Quality Assurance Initiatives for Lesotho Laboratories</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Institute for Communicable Diseases	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 10457			
<b>Mechanism Name:</b> Quality Assurance Initiatives for Lesotho Laboratories			
<b>Prime Partner Name:</b> National Institute for Communicable Diseases			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0		Redacted
LAB_CAP_DSD	By clinical laboratories	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	0		Redacted

## Implementing Mechanism Details

<b>Mechanism ID:</b> 10458	<b>Mechanism Name:</b> MCHIP - Maternal and Child
----------------------------	---------------------------------------------------





	<b>Health Implementation Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10458		
<b>Mechanism Name:</b>	MCHIP - Maternal and Child Health Implementation Program		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10459</b>	<b>Mechanism Name: Strengthening Clinical Services (SCS)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 10459			
<b>Mechanism Name:</b> Strengthening Clinical Services (SCS)			
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	346	

	mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	360	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	346	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	264	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	82	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	346	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	346	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,300	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,352	
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,300	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	992	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	308	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,300	
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,300	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,418	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,443	
PMTCT_STAT_DSD	By: Known positives at entry	157	
PMTCT_STAT_DSD	By: Number of new positives identified	200	

PMTCT_STAT_DSD	Sum of Positives Status disaggregates	357	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,333	
PMTCT_STAT_TA	Number of new ANC and L&D clients	5,430	
PMTCT_STAT_TA	By: Known positives at entry	590	
PMTCT_STAT_TA	By: Number of new positives identified	762	
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,352	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,458	
HTC_TST_DSD	By Test Result: Negative	4,973	
HTC_TST_DSD	By Test Result: Positive	1,485	
HTC_TST_DSD	Sum of Test Result disaggregates	6,458	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	974	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,595	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	965	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,924	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,939	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,519	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,458	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,295	
HTC_TST_TA	By Test Result: Negative	18,707	
HTC_TST_TA	By Test Result: Positive	5,588	
HTC_TST_TA	Sum of Test Result disaggregates	24,295	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,663	

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,002	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,632	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,998	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,295	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	17,000	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	24,295	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	9,746	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	584	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,631	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	586	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,945	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	9,746	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	9,746	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,440	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,600	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting	285	

	period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	357	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	218	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	67	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	285	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,213	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	284	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,185	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	284	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,460	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	568	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,645	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,213	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	20,191	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,069	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	5,527	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,066	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	12,529	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,135	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	18,056	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	20,191	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,292	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	72	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	355	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	71	



	Female		
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	794	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,292	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	675	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	808	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	6,433	
TB_SCREEN_DSD	Sex: Male	1,930	
TB_SCREEN_DSD	Sex: Female	4,503	
TB_SCREEN_DSD	Sum of Sex disaggregates	6,433	

### Implementing Mechanism Details

<b>Mechanism ID: 10739</b>	<b>Mechanism Name: Support to the Ministry of Health and Social Welfare in Lesotho for HIV/AIDS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare – Lesotho	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>





GHP-State	0
-----------	---

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10739		
<b>Mechanism Name:</b>	Support to the Ministry of Health and Social Welfare in Lesotho for HIV/AIDS		
<b>Prime Partner Name:</b>	Ministry of Health and Social Welfare – Lesotho		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11018</b>	<b>Mechanism Name: Peace Corps</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 117,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	117,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 11018			
<b>Mechanism Name:</b> Peace Corps			
<b>Prime Partner Name:</b> U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	72,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	600	4,232
OVC_SERV_TA	Sex: Male	300	
OVC_SERV_TA	Sex: Female	300	
OVC_SERV_TA	Sum of Sex disaggregates	600	
OVC_SERV_TA	Age: <1	0	
OVC_SERV_TA	Age: 1-4	0	
OVC_SERV_TA	Age: 5-9	0	
OVC_SERV_TA	Age: 10-14	200	
OVC_SERV_TA	Age: 15-17	200	
OVC_SERV_TA	Age: 18+	200	
OVC_SERV_TA	Sum of Age disaggregates	600	



### Implementing Mechanism Details

<b>Mechanism ID: 11030</b>	<b>Mechanism Name: PEPFAR Small Grants Program</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	30,000
Gender: Gender Equality	20,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Education	60,000

### Key Issues



(No data provided.)

### Budget Code Information

<b>Mechanism ID: 11030</b>			
<b>Mechanism Name: PEPFAR Small Grants Program</b>			
<b>Prime Partner Name: U.S. Department of State</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	60,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,500	790
OVC_SERV_DSD	Sex: Male	1,000	
OVC_SERV_DSD	Sex: Female	1,500	
OVC_SERV_DSD	Sum of Sex disaggregates	2,500	
OVC_SERV_DSD	Age: 10-14	1,000	
OVC_SERV_DSD	Age: 15-17	1,000	
OVC_SERV_DSD	Age: 18+	500	
OVC_SERV_DSD	Sum of Age disaggregates	2,500	

### Implementing Mechanism Details

<b>Mechanism ID: 12098</b>	<b>Mechanism Name: Support to the Government</b>
----------------------------	--------------------------------------------------



	<b>of the Kingdom of Lesotho (GOL) to Strengthen and Expand Safe Blood Transfusion Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare – Lesotho	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12098		
<b>Mechanism Name:</b>	Support to the Government of the Kingdom of Lesotho (GOL) to Strengthen and Expand Safe Blood Transfusion Services		
<b>Prime Partner Name:</b>	Ministry of Health and Social Welfare – Lesotho		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HMBL	0	0
------------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13484</b>	<b>Mechanism Name: PSI/DOD support</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b> 13484			
<b>Mechanism Name:</b> PSI/DOD support			
<b>Prime Partner Name:</b> Population Services International			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13981</b>	<b>Mechanism Name: TARGET: Increasing access to HIV counseling, testing and enhancing HIV/ADIS prevention</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,099,363</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,099,363

### Sub Partner Name(s)

(No data provided.)





### Cross-Cutting Budget Attribution(s)

Human Resources for Health	70,000
Key Populations: FSW	40,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	40,000
Education	30,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13981		
<b>Mechanism Name:</b>	TARGET: Increasing access to HIV counseling, testing and enhancing		
<b>Prime Partner Name:</b>	HIV/ADIS prevention		
	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,099,363	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the	20,000	13,746	Redacted

	reporting period.			
PP_PREV_DSD	Age/sex: 10-14 Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	220	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	3,604	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	15,502	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0	7,055	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	168	6,691	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	505	0	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	19,999	13,746	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,480	163,781	Redacted
HTC_TST_DSD	By Test Result: Negative	99,858	145,480	Redacted
HTC_TST_DSD	By Test Result: Positive	17,622	18,301	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	117,480	163,781	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,175		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,175		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	8,224		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	35,244		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,699		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,175		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	10,573		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	21,146		Redacted

HTC_TST_DSD	Age/sex: 25-49 Female	29,370		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,699		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	117,480		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,175	10,419	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,342	68,606	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,175	22,602	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	65,789	62,154	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,350	33,021	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	115,131	130,760	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	117,481	163,781	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13983</b>	<b>Mechanism Name: Human Resources Alliance for Africa - HRAA</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern, Central and Southern African Health Community Secretariat	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13983			
<b>Mechanism Name:</b> Human Resources Alliance for Africa - HRAA			
<b>Prime Partner Name:</b> Eastern, Central and Southern African Health Community Secretariat			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1	
HRH_PRE	By Graduates: Doctors	1	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	Sum of Graduates disaggregated	1	

### Implementing Mechanism Details

<b>Mechanism ID:</b> 13987	<b>Mechanism Name:</b> STRENGTHENING TB/HIV
----------------------------	---------------------------------------------



	<b>COLLABORATION IN THE KINGDOM OF LESOTHO</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13987		
<b>Mechanism Name:</b>	STRENGTHENING TB/HIV COLLABORATION IN THE KINGDOM OF LESOTHO		
<b>Prime Partner Name:</b>	Columbia University Mailman School of Public Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	0		Redacted

	during pregnancy and delivery			
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,030		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,538		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14072</b>	<b>Mechanism Name: Systems for Improved Access to Pharmaceuticals and services (SIAPS)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	



<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14072		
<b>Mechanism Name:</b>	Systems for Improved Access to Pharmaceuticals and services (SIAPS)		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2015</b>	<b>2016</b>
HRH_PRE	Number of new HCW who graduated from a	0	





	pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		
HRH_PRE	By Graduates: Other	0	
HRH_PRE	Sum of Graduates disaggreagtes	0	

### Implementing Mechanism Details

<b>Mechanism ID: 14301</b>	<b>Mechanism Name: LETLAMA</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 625,785</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	475,785
GHP-USAID	150,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 14301			
<b>Mechanism Name:</b> LETLAMA			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	625,785	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	35,000	58,437
PP_PREV_DSD	Age/sex: 15-19 Male	1,800	0
PP_PREV_DSD	Age/sex: 20-24 Male	6,000	11,325
PP_PREV_DSD	Age/sex: 25-49 Male	15,000	15,648
PP_PREV_DSD	Age/sex: 15-19 Female	1,800	10,676
PP_PREV_DSD	Age/sex: 20-24 Female	6,000	10,971
PP_PREV_DSD	Age/sex: 25-49 Female	4,400	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	35,000	58,437
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,000	5,459
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	1,000	3,380



	evidence and/or meet the minimum standards required)		
--	------------------------------------------------------	--	--

### Implementing Mechanism Details

<b>Mechanism ID: 16766</b>	<b>Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,007,264</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,007,264

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16766</b>
----------------------------



<b>Mechanism Name:</b>	<b>Applying Science to Strengthen and Improve Systems (ASSIST)</b>		
<b>Prime Partner Name:</b>	<b>University Research Corporation, LLC</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	2,507,264	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	210,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	120,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	750,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	120,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16768</b>	<b>Mechanism Name: Mentor Mothers Reducing Infections Through Support and Education (RISE)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	800,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16768		
<b>Mechanism Name:</b>	Mentor Mothers Reducing Infections Through Support and Education		
<b>Prime Partner Name:</b>	(RISE) Mothers 2 Mothers		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	400,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,710	
PP_PREV_DSD	Total number of people in the target population	4,710	

### Implementing Mechanism Details

<b>Mechanism ID: 17123</b>	<b>Mechanism Name: CDC HMIS support to the MOH</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 686,640</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	686,640

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues



(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17123			
<b>Mechanism Name:</b> CDC HMIS support to the MOH			
<b>Prime Partner Name:</b> Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	686,640	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17401	<b>Mechanism Name:</b> Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 6,235,584</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,235,584

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,000,000
Motor Vehicles: Purchased	50,000
Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: GBV	10
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research





## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17401			
<b>Mechanism Name:</b> Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)			
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	321,107	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	786,831	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	633,298	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	498,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,898,677	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,097,671	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,571	3,172	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,654	3,210	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	714		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	940	1,272	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	714	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	940	3,172	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,356		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,480		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,071		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,409		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,071	0	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,409		Redacted
PMTCT_STAT_DS	Number of pregnant women with known	6,264	13,063	Redacted

D	HIV status (includes women who were tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	6,392	13,750	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	940	1,613	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	714	1,586	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,654	3,199	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,395		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	9,587		Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,409		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,071		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,480		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	46,763	185,096	Redacted
HTC_TST_DSD	By Test Result: Negative	37,410	160,531	Redacted
HTC_TST_DSD	By Test Result: Positive	9,353	24,565	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	46,763	185,096	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,068		Redacted
HTC_TST_TA	By Test Result: Negative	52,054		Redacted
HTC_TST_TA	By Test Result: Positive	13,014		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	65,068		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting	73,537		Redacted

	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	28,277	26,885	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,757	1,104	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,196	1,781	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,175	3,210	Redacted
PMTCT_EID_DSD	Number of HIV-positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,969		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,905	2,471	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,270	738	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,175	3,209	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,580	49,006	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	673		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,677		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	671		Redacted

TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,559		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,344		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	8,236		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,580		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	48,220		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,531		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	13,220		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,525		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	29,944		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	5,056		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	43,164		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	48,220		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,705	20,534	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	643		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,890		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	642		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,530		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,705		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	46,574	59,015	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting	73,537		Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
--	----------------------------------------------------------------------	--	--	--

### Implementing Mechanism Details

<b>Mechanism ID: 17427</b>	<b>Mechanism Name: LDF Electronic Medical Records</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 17427</b>
----------------------------



<b>Mechanism Name:</b>	LDF Electronic Medical Records		
<b>Prime Partner Name:</b>	VISTA PARTNERS		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17429</b>	<b>Mechanism Name: VMMC Mechanism</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 550,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	550,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom programming	10,000
Condom procurement	10,000



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17429			
<b>Mechanism Name:</b> VMMC Mechanism			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID:</b> 17430	<b>Mechanism Name:</b> Building global capacity for diagnostic testing of tuberculosis, malaria and HIV
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Innovative New Diagnostics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:





<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17430		
<b>Mechanism Name:</b>	Building global capacity for diagnostic testing of tuberculosis, malaria and HIV		
<b>Prime Partner Name:</b>	Foundation for Innovative New Diagnostics		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016	Planning Budget Targets



LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	0		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0		Redacted
LAB_CAP_DSD	By clinical laboratories	0		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	0		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 17431</b>	<b>Mechanism Name: Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,067,400</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,067,400

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	300,000
Motor Vehicles: Purchased	100,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17431		
<b>Mechanism Name:</b>	Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under		
<b>Prime Partner Name:</b>	the President's Emergency Plan for AIDS Relief (PEPFAR) University Research Corporation, LLC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	483,480	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	903,436	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	123,392	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	550,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	883,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	123,392	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	3	5	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	3		Redacted



LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	236	11	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	20		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	216		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	236		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	236		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	0		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 17432</b>	<b>Mechanism Name: Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 407,364</b>	
-------------------------------------------	--



<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	407,364

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	100,000
----------------------------	---------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17432		
<b>Mechanism Name:</b>	Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)		
<b>Prime Partner Name:</b>	Ministry of Health (MOH)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	50,001	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Governance and Systems	HLAB	57,363	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	50,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	8,500		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,000		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,275		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	7,225		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,500		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	425		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing	3	2	Redacted



	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	3		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	236	2	Redacted
LAB_CAP_DSD	By clinical laboratories	20	2	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	216	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	20		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	216		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	236		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	236		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 17467</b>	<b>Mechanism Name: Accelovate</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:





<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17467			
<b>Mechanism Name:</b> Accelovate			
<b>Prime Partner Name:</b> JHPIEGO			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	53,500	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	85	
VMMC_CIRC_DSD	By Age: 10-14	11,175	
VMMC_CIRC_DSD	By Age: 15-19	21,900	
VMMC_CIRC_DSD	By Age: 20-24	9,870	
VMMC_CIRC_DSD	By Age: 25-49	10,195	
VMMC_CIRC_DSD	By Age: 50+	275	
VMMC_CIRC_DSD	Sum of age disaggregates	53,500	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	5,350	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	52,500	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,000	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	48,150	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	5,350	
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the	1,500	

	reporting period		
VMMC_CIRC_TA	By Age: <1	1,500	
VMMC_CIRC_TA	By Age: 1-9	0	
VMMC_CIRC_TA	By Age: 10-14	0	
VMMC_CIRC_TA	By Age: 15-19	0	
VMMC_CIRC_TA	By Age: 20-24	0	
VMMC_CIRC_TA	By Age: 25-49	0	
VMMC_CIRC_TA	By Age: 50+	0	
VMMC_CIRC_TA	Sum of Age disaggregations	1,500	
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	150	
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	1,500	
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,350	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	150	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	49,500	
HTC_TST_TA	By Test Result: Negative	46,530	
HTC_TST_TA	By Test Result: Positive	2,970	
HTC_TST_TA	Sum of Test Result disaggregates	49,500	
HTC_TST_TA	Age/sex: <1 Male	1,500	



HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	85	
HTC_TST_TA	Age/sex: 10-14 Male	11,675	
HTC_TST_TA	Age/sex: 15-19 Male	15,900	
HTC_TST_TA	Age/sex: 20-24 Male	9,870	
HTC_TST_TA	Age/sex: 25-49 Male	10,195	
HTC_TST_TA	Age/sex: 50+ Male	275	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	0	
HTC_TST_TA	Age/sex: 20-24 Female	0	
HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	49,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,900	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	39,600	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	9,900	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	39,600	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	49,500	

### Implementing Mechanism Details

<b>Mechanism ID: 17468</b>	<b>Mechanism Name: CHASE</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,700,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom programming	20,000
Gender: GBV	50,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Commodities	100,000
Key Populations: FSW	70,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	80,000
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Human Resources for Health	200,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17468		
<b>Mechanism Name:</b>	CHASE		
<b>Prime Partner Name:</b>	Elizabeth Glaser Pediatric AIDS Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	363,427	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	364,839	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	345,517	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	152,493	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,004,957	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	468,767	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,037	4,151
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,079	4,233
PMTCT_ARV_DSD	Life-long ART (including Option B+)	1,037	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	791	1,738
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	246	2,413
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	1,037	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	1,037	4,151
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,901	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,057	
PMTCT_ARV_TA	Life-long ART (including Option B+)	3,901	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,975	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on	926	

	treatment at the beginning of the current pregnancy		
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	3,901	0
PMTCT_ARV_TA	Sum of New and Current disaggregates	3,901	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,254	13,810
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,329	14,637
PMTCT_STAT_DSD	By: Known positives at entry	471	2,127
PMTCT_STAT_DSD	By: Number of new positives identified	600	2,122
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,071	4,249
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,999	
PMTCT_STAT_TA	Number of new ANC and L&D clients	16,290	
PMTCT_STAT_TA	By: Known positives at entry	1,770	
PMTCT_STAT_TA	By: Number of new positives identified	2,286	
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4,056	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,664	136,010
HTC_TST_DSD	By Test Result: Negative	15,911	117,583
HTC_TST_DSD	By Test Result: Positive	4,753	18,427
HTC_TST_DSD	Sum of Test Result disaggregates	20,664	136,010
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,116	8,699
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,104	35,373
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,089	9,760
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,355	82,178
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,205	18,459



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	14,459	117,551
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,664	136,010
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	77,744	
HTC_TST_TA	By Test Result: Negative	59,862	
HTC_TST_TA	By Test Result: Positive	17,882	
HTC_TST_TA	Sum of Test Result disaggregates	77,744	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,723	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,205	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,622	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	35,194	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	23,345	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	54,399	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	77,744	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	28,341	75,649
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,545	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,657	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,831	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,308	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	28,341	
CARE_CURR_TA	Number of HIV positive adults and children	105,491	

	who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,812	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,807	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,759	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	65,113	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	105,491	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	11,230	25,651
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	625	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	3,078	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	620	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	6,907	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	11,230	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	11,230	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,342	298
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,677	298
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	4,319	1,734

	the reporting period		
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,799	2,865
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	856	4,583
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,071	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	655	3,528
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	201	1,055
PMTCT_EID_DSD	Sum of Infant Age disaggregates	856	4,583
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,431	65,661
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	907	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,777	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	903	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,844	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,810	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	11,621	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,431	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	64,374	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	3,409	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	17,621	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	3,398	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	39,946	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	6,807	



TX_CURR_TA	Sum of Aggregated Age/Sex 15+	57,567	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	64,374	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,669	16,696
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	270	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,287	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	267	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,845	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,669	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,015	12,484
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,669	13,855
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	26,640	66,171
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	28,341	75,649
TB_SCREEN_DSD	Sex: Male	7,992	22,042
TB_SCREEN_DSD	Sex: Female	18,648	44,129
TB_SCREEN_DSD	Sum of Sex disaggregates	26,640	66,171
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	105,491	



	OR viral load		
--	---------------	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 17547</b>	<b>Mechanism Name: Food and Nutrition Technical Assistance III Project (FANTA)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17547
<b>Mechanism Name:</b>	Food and Nutrition Technical Assistance III Project (FANTA)
<b>Prime Partner Name:</b>	FHI 360



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17549</b>	<b>Mechanism Name: TSEPO</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,557,083</b>	
<b>Applied Pipeline Amount: 275,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,557,083

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17549			
<b>Mechanism Name:</b> TSEPO			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	109,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,447,210	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17554	<b>TBD:</b> Yes
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17557	<b>Mechanism Name:</b> Livelihoods and Food Security Technical Assistance Project II (LIFT II)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	



Funding Source	Funding Amount
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17557			
<b>Mechanism Name:</b> Livelihoods and Food Security Technical Assistance Project II (LIFT II)			
<b>Prime Partner Name:</b> FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17622	<b>TBD:</b> Yes
<b>REDACTED</b>	

**Implementing Mechanism Details**





<b>Mechanism ID: 18020</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18048</b>	<b>Mechanism Name: Global Health Supply Chain Management</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Chemonics. Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	2,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID: 18048</b>			
<b>Mechanism Name: Global Health Supply Chain Management</b>			
<b>Prime Partner Name: Chemonics. Inc</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	210,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	120,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	120,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18143</b>	<b>Mechanism Name: 4Children – Coordinating Comprehensive Care for Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N/A

G2G: No      Managing Agency:

**Total All Funding Sources: 0**

**Applied Pipeline Amount: 0**

Funding Source	Funding Amount
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18143			
<b>Mechanism Name:</b> 4Children – Coordinating Comprehensive Care for Children			
<b>Prime Partner Name:</b> Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing			126,767	126,767	0
Computers/IT Services			120,800	120,800	0
ICASS			800,698	800,698	0
Management Meetings/Professional Development			98,000	98,000	0
Non-ICASS Administrative Costs			100,000	100,000	0
Staff Program Travel			191,857	191,857	0
USG Staff Salaries and Benefits			2,011,878	2,011,878	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>3,450,000</b>	<b>3,450,000</b>	<b>0</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		40,000		40,000	0
Institutional Contractors				0	0



Management Meetings/Professional Development		10,000		10,000	0
Non-ICASS Administrative Costs		5,000		5,000	0
Peace Corps Volunteer Costs				0	0
Staff Program Travel		15,000		15,000	0
USG Staff Salaries and Benefits		65,000		65,000	0
<b>Total</b>	<b>0</b>	<b>135,000</b>	<b>0</b>	<b>135,000</b>	<b>0</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		208,980		208,980	0
Computers/IT Services		40,000		40,000	0
ICASS		705,277		705,277	0
Institutional Contractors		181,456		181,456	0
Management Meetings/Professional Development		22,000		22,000	0
Non-ICASS Administrative Costs		208,695		208,695	0



Staff Program Travel	0	184,350		184,350	0
USG Staff Salaries and Benefits	512,500	636,742		1,149,242	0
<b>Total</b>	<b>512,500</b>	<b>2,187,500</b>	<b>0</b>	<b>2,700,000</b>	<b>0</b>

### U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		60,000		60,000	0
Non-ICASS Administrative Costs		60,000		60,000	0
Staff Program Travel		20,000		20,000	0
USG Staff Salaries and Benefits		60,000		60,000	0
<b>Total</b>	<b>0</b>	<b>200,000</b>	<b>0</b>	<b>200,000</b>	<b>0</b>

### U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		37,399		37,399	0
Peace Corps Volunteer Costs		370,942		370,942	0
Staff Program		21,168		21,168	0



Travel					
USG Staff Salaries and Benefits		90,491		90,491	0
<b>Total</b>	<b>0</b>	<b>520,000</b>	<b>0</b>	<b>520,000</b>	<b>0</b>